Physician profile
Tripta Sachdev
NPI 1144288713
$4,285.11
in general payments reported to CMS, 2019-2025
43 companies · $698 in 2025
The $698 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $329 · 2021: $492 · 2022: $168 · 2023: $581 · 2024: $766 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $485.72 | 2019-2025 | Ultomiris |
| Abbvie INC. | $361.37 | 2019-2025 | Botox |
| Catalyst Pharmaceuticals, INC. | $357.56 | 2023-2025 | Fycompa |
| Lundbeck LLC | $226.04 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $212.96 | 2019-2024 | |
| Akcea Therapeutics, INC. | $202.86 | 2019 | |
| Neurelis, INC. | $183.81 | 2024-2025 | Valtoco |
| Eisai INC. | $180.36 | 2019-2025 | |
| Ucb, INC. | $178.12 | 2019-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $163.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $148.36 | 2023-2025 | |
| Biogen, INC. | $130.58 | 2019-2022 | |
| Genzyme Corporation | $110.98 | 2019-2023 | |
| Lilly USA, LLC | $104.74 | 2022-2025 | Amyvid, Kisunla |
| Medtronic Vascular, INC. | $98.47 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tripta Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.